Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for Eosinophilic Esophagitis With Severe Strictures
NCT06352073Phase 4Active, not recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- May 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dupilumab in eosinophilic esophagitis (EoE), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Histologic Response to Dupilumab at 24 weeks. Started May 2024; status: active, not recruiting.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT06352073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06352073.